The purpose of this mono therapy study is to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of BCD-145 (JSC BIOCAD, Russia) in patients with unresectable/metastatic melanoma.

Trial Profile

The purpose of this mono therapy study is to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of BCD-145 (JSC BIOCAD, Russia) in patients with unresectable/metastatic melanoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Anti-CTLA-4 monoclonal antibody (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Biocad
  • Most Recent Events

    • 23 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top